C2 PHARMA, a Luxembourg-based API manufacturer and distributor, is announcing that they will open access to safety stocks of the active pharmaceutical ingredient Digoxin after initial research in South Korea and India noted the API's potential to reduce the symptoms of COVID-19 patients in combination with other anti-viral drugs.
According to the company, Digoxin is extracted from the digitalis lanata plant. Due to the structure of the ingredient, it cannot be manufactured synthetically, so there is no way for API manufacturers to respond quickly to demand peaks. As the leading manufacturer of Digoxin API for the pharmaceutical industry, C2 PHARMA holds safety stocks to ensure supply as a standard operating procedure. Based on initial findings of ongoing research, the company has decided to open its safety stocks of Digoxin API to governments and to the global research community in order to meet any peaks in demand.
C2 PHARMA is offering samples of Digoxin API free of charge to bona fide members of the research community and clinicians working on COVID-19 efficacy trials.
Verified government and research contacts may reach out to the company directly at [email protected] to inquire about supply.
Read the press release here
